SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-23-000075
Filing Date
2023-05-08
Accepted
2023-05-08 16:06:15
Documents
57
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20230331.htm   iXBRL 10-Q 1464865
2 EX-31.1 exhibit311q12023.htm EX-31.1 9993
3 EX-31.2 exhibit312q12023.htm EX-31.2 10013
4 EX-32.1 exhibit321q12023.htm EX-32.1 5652
5 EX-32.2 exhibit322q12023.htm EX-32.2 5781
  Complete submission text file 0001714899-23-000075.txt   5677603

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20230331.xsd EX-101.SCH 37838
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20230331_cal.xml EX-101.CAL 45583
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20230331_def.xml EX-101.DEF 188813
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20230331_lab.xml EX-101.LAB 456420
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20230331_pre.xml EX-101.PRE 304903
51 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20230331_htm.xml XML 797857
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 23897734
SIC: 2836 Biological Products, (No Diagnostic Substances)